Good day and welcome to the Long Geveron 2026 Second Quarter Financial Results Conference Call. If you would like to ask a question today, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 to remove yourself from the queue. For participants using speaker equipment, it may be necessary to pick up the handset before pressing the star keys. Please be advised that today's conference is being recorded. I would now like to hand the call over to Derek Cole of Investor Relations Advisory Solutions. Please go ahead, sir.

Thank you, Rochelle. Good afternoon, everyone, and thank you for joining us today to review Longevron's 2026 second quarter financial results and business update. After the U.S. markets closed today, we issued a press release with financial results for the second quarter, which can be found under the Investor section of the Longevron website. On the call today are Stephen Willard, Chief Executive Officer, Dr. Joshua Hare, Co-Founder, Chief Science Officer, and Executive Chairman of the Board, Dr. Natalia Agafinova, Chief Medical Officer, Devin Blass, Chief Technology Officer, and Marie Washburn, Chief Financial Officer. As a reminder, during this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in the company's filings with the Securities and Exchange Commission, which we encourage you to review. Following the company's prepared remarks, we will open the call to questions from covering analysts. With that, let me hand the call over to Stephen Willard, Chief Executive Officer. Steve?

Thank you, Derek, and thank you all for joining us today. This is an incredibly important and exciting time for the company. Longevron is approaching a series of potentially transformative milestones across our four stem cell therapy development programs that have the potential to redefine the trajectory of our business. As a reminder, we are developing Laramester Cell in poor indications with high unmet medical needs, hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and age-related frailty. We have focused on our development activities to prioritize our most important near-term catalyst, the data readout from ELPIS-2, our Phase 2B clinical trial evaluating Laramester cell in HLHS. We expect to report that data readout in mid-September. Our approach to stem cell therapy development has garnered external recognition and validation with encouraging data from our clinical trials having been published in Nature Medicine and Cell Stem Cell. Additionally, as you hopefully saw in our announcement yesterday, published clinical trial results which indicate laramester cell increases six-minute walk distance in patients with age-related frailty where the basis for our selection is a finalist for the XPRIZE HealthSpan competition. XPRIZE HealthSpan is a seven-year, $101 million global competition to revolutionize the way we approach human aging. We are extremely humbled to appreciate and appreciate to have our stem cell therapy, Laramester Cell, recognized in this manner. We believe that we are the only publicly traded company to receive this honor. X-Prize team applications were rigorously evaluated for scientific merit and clinical readiness to identify the best, most feasible, and safe approaches to increase human health The Milestone II awardees out of more than 600 applicants across 58 countries were selected as finalist awardees. The X-Prize criteria was that finalist awardees must present a single or combination therapeutic approach that demonstrates feasibility and potential to restore or preserve muscular, cognitive, and immune function lost to age-related degradation by at least 10 years with the ambitious goal of 20 years, and deliver the therapy in one year or less in adults age 50 to 90 who are free of major or life-threatening disease and disability. The top milestone, two award-winning teams each receive $1 million to advance their therapeutic approach into the final phase of the competition, where teams will conduct coordinated clinical trials through 2029. The grand prize will award up to $81 million to the winning team. We look forward to the next chapter of the competition as we continue to develop our stem cell therapy that we believe has the potential to have a significant impact for patients and their families and extend healthy life. We believe the strength of our historical clinical data, external validation of our programs, and hopefully the ELPIS II data provide Longeviron with ideal timing to explore potential development and commercialization partnerships. We believe that leveraging the commercial infrastructure, capital resources, and global reach of established pharmaceutical partners represents the most efficient pathway to unlock the full value of our assets. It is a very exciting time for Laramestracel, the patients we serve, Longeviron, and our shareholders. With that, I will turn the call over to Dr. Agafonava, our Chief Medical Officer, to touch on our clinical trial development programs. Natalia.

Thank you, Steve. Good afternoon, everyone. As Steve mentioned, our HLHS program is the primary focus for us, with top-line results from the LPS2 trial anticipated over the next month. We look forward to sharing those results when they're available. LPS2 is evaluating laramistrocelle as a potential adjunct treatment for hypoplastic left heart syndrome, or HLHS. HLHS is a rare pediatric congenital heart birth defect in which the left ventricle, one of the pumping chamber of the heart, is either severely underdeveloped or missing. We agree with the FDA that only the most objective measures, including all-cause mortality, cardiac transplant-free survival, event of cardiac transplantation, and well-defined measure adverse cardiac events could be informative of efficacy of LPS2. We have captured all of these measures in LPS2 along with some additional key measures to support an efficacy determination. We are also continued with planning and preparation this year for a potential initiation in 2027 of a phase two clinical trial in pediatric dilated cardiomyopathy or PDCM. This is a rare pediatric cardiovascular disease in which the muscle in one or more of the heart chambers become enlarged or stretched or dilated with nearly 40% of children with PDCM requiring a heart transplant or dying within two years of diagnosis. Our investigational new drug IND application for laramistrocell for potential treatment of pediatric deleted cardiomyopathy became effective in July 2025. This IND allows advancement directly into a single phase two registrational clinical trial, reflecting the serious nature of this rare pediatric disease and the significant unmet medical need. I will hand the call over to Marie Warsburg, our Chief Financial Officer. Marie?

Thank you, Natalia, and good afternoon, everyone. This afternoon, we issued a press release and filed our quarterly report on Form 10-Q, both of which are financial results in detail. So I will touch on some highlights. Revenues for the three-month period ended June 30, 2026, and June 30, 2025 were $0.3 million. 2026 revenues decreased by 29 000 or 10 percent when compared to 2025 primarily due to the absence of contract manufacturing revenue general and administrative expenses for three months ended june 30th 2026 were 3.2 million compared to 2.6 million for the same period in 2025 The increase of $0.6 million, or 23%, were primarily due to $0.4 million increase in legal spend and $0.2 million increase in personnel costs. Research and development expenses were $3.2 million for the three months ended 2026 compared to $3 million for the same period in 2025. The increase of $0.2 million, or 7%, was due to higher clinical trial expenses to support the ELPIS-2 top-line results expected in September. Net loss was $6.1 million for the three months ended June 30, 2026, compared to $5 million for the three months ended 2025. The increase of 1.1 million, or 22%, was due to the factors outlined above. Our cash and cash equivalents as of June 30, 2026, was 10.1 million. We currently anticipate our current existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditures into the fourth quarter of 2026. based on our current operating budget. I will hand over the call to Josh Hare, a co-founder and CSO. Josh?

Thank you, Marie. Good afternoon, everyone. As we rapidly approach the availability of top-line data from the ELPAS II Phase II B trial in HLHS, I want to highlight some of the progress and accomplishments that underpin our belief in our allergenic mesenchymal stem cell therapy, Laramestercel and support its potential application across multiple high-value indications. First, strong foundational science. Laramestercel has multiple potential mechanisms of action that include anti-inflammatory, provascular, and pro-regenerative effects. Laramestercel is supported by a portfolio of 52 issued patents with over 60 pending patents worldwide. We have five FDA-expedited designations, including Regenerative Medicine Advanced Therapy, or ARMAT, FastTrack, Orphan Drug, and Rare Pediatric Disease. Longevron has completed and has encouraging initial results warranting further investigation across five clinical trials and three separate indications. We have promising data from our clinical trials that have been published in prestigious journals such as Nature Medicine and Cell Stem Cell. We have favorable clinical trial results in aging frailty, supporting selection as a finalist out of over 600 development projects submitted worldwide for the XPRIZE Healthspan Competition, which also comes with a $1 million award. We continue to make progress across our entire development pipeline and look forward to sharing the results of ELPIS II shortly. I'll now turn the call back to Stephen.

Thank you, Josh. The anticipated near-term clinical data for HLHS, the strengthening of our balance sheet, the support of high-quality fundamental investors, and the potential for partnerships across our development programs make this an extraordinarily exciting time for Longevron. We deeply appreciate the support of all of our stakeholders and look forward to continuing collaboration and progress in the future. Operator, we would now like to open the call for questions from our covering analysts.

Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 to remove yourself from the queue. For participants using speaker equipment, it may be necessary to pick up the handset before pressing the star keys. One moment while we poll for questions. And our first question, we'll hear from Ram Salavaro with H.C. Wainwright.

Thanks so much for taking our questions, and congratulations on all the recent progress. Definitely coming up on exciting times here. I wanted to see if you could elaborate on the updated outlook for Laramestracel in HLHS, specifically as this pertains to the following three items. Firstly, the timeline with which you anticipate a regulatory submission could be completed for filing upon generation of positive data from ELPIS-2. Secondly, where you are with respect to commercial scale-up and how that dovetails with the underlying market demand that you anticipate for Laramestracell upon potential approval in HLHS. And lastly, any updated thoughts or feedback with respect to potential pricing discussions or the relative value proposition that you anticipate Laramestracel would be associated with from the payer standpoint? And then just a very quick question on the age-related frailty aspect. In the event that Laramestercel ultimately received the top prize in the XPRIZE competition, how would this affect the company's strategic planning for future development of the drug in the age-related frailty indication?

Wow. That's quite a list of questions. Let me see if I can get to them in the order you provided. First of all, the timetable is we are eagerly looking forward to having an auction among partners of choice in the event of good HLHS data. and a partnership will determine some of the things like pricing and that sort of thing. We anticipate, we've already had conversations with major potential partners and we think they are expert at pricing and timetable and that sort of thing. We don't see any blockers if we get good HLHS data to going to a BLA with, I would remind you, a priority review voucher, which just recently sold for $215 million. There's also a potential priority review voucher available with regard to our PDCM, which we'll be starting next year. I've discussed the timetable, the manufacturing, the pricing discussions, And then with regard to this XPRIZE, I think it's extraordinary to have a company. I mean, we are known as a company, despite 12 years in the longevity space, as experts in rare pediatric orphan drugs. And that is part of our mandate. But we really have extraordinary data with regard to longevity. We will very much seek to partner in longevity prior to winning the XPRIZE and the $81 million. And I think it's a very fertile area that a lot of people are appreciating. And as I noted, of the XPRIZE winners, I believe we are the only public company, the only one that people can invest in, in terms of the cutting edge of longevity research today. Did I hit your questions, Ram?

Yes, thank you very much.

And our next question, we'll hear from Bubalan, Pecheyem and Pitpal with Roth Capital Partners.

Hi, good afternoon, everyone. Thanks for taking our questions. So we have three or four maybe. I wanted to start off our discussion with a focus on statistical analysis plan or FAP, to say it in a short form. Because this is a hot button issue, they say, with all the outcome stuff that we witnessed a couple of weeks ago. So I'm compelled to ask a few questions based on this topic and some of them we might have discussed in the past. So where are you in terms of FAP alignment with the FDA? are there any last-minute changes that needed to be made to the SAP protocol prior to database unblinding? And also a sub-question, again, on the SAP. Is the lack of SAP alignment with the FDA the reason for pushing the deadline from August to September?

I can tell you – well, actually, Natalia, would you answer that question?

Yeah, absolutely. Thank you for your questions. Just to clarify, we have already had substantive discussions with the FDA in alignment regarding their end point strategy, which includes both NIH defined and sponsor defined end points. And we have incorporated all the agency feedback into our statistical plan, statistical approach. So we subsequently submitted the SAP to FDA for review, and we're still waiting for their feedback. If we don't receive additional comments before database lock, we currently intend to proceed with the plan database lock, conduct analysis, pre-specified analysis according to the prospectively finalized SAP. So, I don't think there's anything unresolved, we so far resolved all the FDA agencies' questions, incorporated them to statistical analysis plan, and of course, if we get them prior to database lock, we're happy to, you know, just to clarify some and incorporate the details about this up. And second question you're asking about August versus September is not going to affect anything. So we were waiting for the last patient last visit. There were a few delays in MRI month 12 last patient last visit. That was the reason why we slightly delay our database, but so far it's planned on August 31st with the top line results data available in September.

All right. So moving on, let's say your former primary endpoint, which is RVEF, let's say the RVEF was not met in your LPS2, but you're seeing improvements in, let's say, the length of hospitalization, the transplant-free survival, and adverse evens. And let's say you're hitting statistical significance in all of this. Can you regain the pivotal status and file a BLA based off of that? Or put it differently, what would be the minimum efficacy package that would justify a BLA submission?

There are a lot of precedences when sponsors approved biologics had an exploratory endpoint, with exploratory endpoints. So we already know that FDA expressed opinion that the most clinically significant endpoints, which we already incorporated in our analysis, such as all-cause mortality, hospitalization, et cetera, they will consider this as exploratory. However, they are happy to exercise regulatory flexibility, and they requested to share results of our trial with them, see for potential, you know, potential approval. So absolutely, if in case if you, the option you describe in case of right ventricle ejection fraction doesn't hit statistical significance, but the sponsor-defined criteria met, they absolutely do everything possible to regain BLA status.

Yes. And remember here, this is a very devastating disease for which there is not alternative medicines available. And the FDA has been quite positive in saying they want to work with us despite the challenges we've had. And I think that we're collecting the data which, if successful, could encourage the FDA to give us the pivotal and BLA status.

Okay. Maybe one last question. Let's say LPS2 supports a BLA path. What are the remaining CMC items that needs to be checked? Or maybe what are the other items that needs to be checked for a BLA filing, say, sometime in 2027? Thank you.

Kevin, I'll take this one. We have made excellent progress with our CMC. We have a provider that we are working actively with to transfer the manufacturing. I think everything looks to be a go. We'll be able to fine-tune our program once we have a partner, but I think the partner was probably going to allow us and agree with us that we are best at handling the manufacturing of this key product. So I don't see any blockers or impediments with a positive signal from the FDA to getting that BLA.

Congratulations again. Thank you.

Thank you.

And our next question we'll hear from Michael Akunowich with Maxim Group.

Hey, guys. Thank you so much for taking my questions. Thank you, Michael. I just wanted to ask a little bit about how you're going to be collecting the events-based data, because it's only a 12-month endpoint for RVEF. So is this something that you're expecting to collect over time and we're planning to do as part of some longer-term follow-up? Or will you have sufficient data to actually see any sort of difference on an events-based outcome at the upcoming September readout?

Thank you, Michael. I might address this. Please. So, Michael, great question. One of the long-term effects on patient outcome we are collecting right before the database lock. for each patient some of the patients initiated the trials five years ago and we have five years data we are collecting survival status uh we are collecting on transplant status this is we're going to have for all patients with different duration they depending on when patient initiated the treatment this is something we will collect at the end of the trial in addition we are planning a long-term expansion trial up to the patients of age of 10. And we already share this plan with FDA. They already submitted their questions. We are addressing them, and we already do infeasibility, et cetera. And our goal is to initiate this trial and continue following up these patients for the long-term outcome up to the patients at 10 years old. With that information, it's a long-term extension study for the survival status. With that information, there are a lot of, we kind of open a lot of regulatory options for us. So we can go for accelerated approval waiting for the long-term extension results, or we can just go for traditional approval still waiting for the results of the long-term extension, which is always reassuring, because the most clinically important effect is a long-term survival, transplant-free survival for this patient population. Certainly.

Thank you for that additional color on it. Are we expecting that you will have sufficient survival data to go back to FDA and potentially file for an FDA this September or our BLA this September? Or is something where we really need to wait and see how the data is before we can determine whether or not it'll be able to serve for approval in the near term.

So for now I think we have sufficient data for yeah we do have sufficient data to demonstrate long-term outcome and at the time of the DLA, we might have even the, you know, additional survival data. So as we continue to collect them, we might have additional data. But at the end of this trial, like at the end of the, in September, we will have already sufficient data to demonstrate five-year survival for some patients.

Thank you. And then one last one. I know this is an exploratory endpoint, but Do you have sufficient patience in the study that you could get some sort of statistical power on the events-based endpoints?

Yes. Even with missing data, and we do have sufficient data, if our assumptions are correct, it's still blended, but we do have sufficient data to demonstrate significance.

All right. I really appreciate your additional clarity. Congrats on all the progress. Thank you for getting involved.

There are no further questions at this time. I would like to turn the floor back to Stephen Willard for closing remarks.

Thank you, Operator, and thank you all for attending today's call. We greatly appreciate your interest and support and look forward to updating you in the coming weeks. Thank you. Operator, you may end the call.

Thank you. This does conclude today's teleconference. We thank you for your participation. You may disconnect your lines at this time.